<Anchor>
Now, the fifth vaccine to enter Korea is Novavax in the US. Half of the total 20 million doses are expected to arrive in the third quarter, and a recent additional clinical trial showed that the preventive effect exceeded 90%.
This information is provided by Yoo Seung-hyeon, medical reporter.
<Reporter>
The phase 3 clinical trial of Novavax vaccine was conducted on 29,960 people in the United States and Mexico.
Two-thirds of the subjects received two doses of the vaccine, three weeks apart, and one-third received a placebo.
The prevention rate was found to be 90.4%.
In the first phase 3 trial conducted in the UK in March, it showed a 96% preventive effect on the existing Corona 19 virus, but this time it showed a high prevention rate even in the situation where the mutant virus has spread.
In particular, for mutations in 8 major species, it was up to 93.2%.
[Stanley Erck/CEO of Novavax: Overall, the efficacy was 90%, which is a very high number considering that there were many mutations during the clinical period.]
Novavax vaccine is a method of directly injecting the antigen protein itself made by genetic recombination technology is.
It is also used for hepatitis B and cervical cancer vaccines.
No serious adverse reactions were observed in previous clinical trials.
Another advantage is that it can be refrigerated between 2-8 degrees Celsius.
Novavax announced that it would seek approval for use in the US and Europe by the end of September.
Korea is also expected to apply at the same time.
We plan to bring in half of the contract volume of 40 million in the third quarter, but it may be delayed.
Even so, if 60 million doses in the third quarter are introduced as scheduled, centered on Pfizer and Moderna vaccines, there will be no major problems.
(Video editing: Kim Jong-mi, CG: Han Jeong-woo, Eom So-min)